Zimmer Biomet
About: Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Employees: 18,000
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
62% more first-time investments, than exits
New positions opened: 133 | Existing positions closed: 82
50% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 9 (+3) [Q4]
1.76% more ownership
Funds ownership: 89.34% [Q3] → 91.09% (+1.76%) [Q4]
1% more funds holding
Funds holding: 964 [Q3] → 972 (+8) [Q4]
2% less capital invested
Capital invested by funds: $19.6B [Q3] → $19.1B (-$463M) [Q4]
21% less repeat investments, than reductions
Existing positions increased: 286 | Existing positions reduced: 363
26% less call options, than puts
Call options by funds: $62.5M | Put options by funds: $84M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$112
7%
upside
Avg. target
$125
19%
upside
High target
$140
34%
upside
7 analyst ratings
5 positive
71%
1 neutral
14%
1 negative
14%
Truist Securities Richard Newitter 77% 1-year accuracy 33 / 43 met price target | 8%upside $113 | Hold Reiterated | 10 Feb 2025 |
Barclays Matt Miksic 72% 1-year accuracy 28 / 39 met price target | 7%upside $112 | Underweight Maintained | 10 Feb 2025 |
RBC Capital Shagun Singh 63% 1-year accuracy 44 / 70 met price target | 19%upside $125 | Outperform Maintained | 7 Feb 2025 |
Raymond James Jayson Bedford 80% 1-year accuracy 20 / 25 met price target | 14%upside $119 | Outperform Maintained | 7 Feb 2025 |
JMP Securities Andrew Boone 83% 1-year accuracy 73 / 88 met price target | 34%upside $140 | Market Outperform Reiterated | 7 Feb 2025 |
Financial journalist opinion
Based on 13 articles about ZBH published over the past 30 days
Negative
Zacks Investment Research
4 days ago
ZBH Stock Hurt by Margin Concerns and Difficult Solvency
Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.
Positive
Seeking Alpha
2 weeks ago
Zimmer Biomet: Adding To The Growth Profile
Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 drug overhang. The 2015 Zimmer Biomet merger hasn't been fully delivered, but recent organic growth and M&A actions are promising, with mid-single digit sales growth projected. The $1.2 billion Paragon 28 acquisition enhances foot and ankle orthopedics, despite short-term EPS dilution, and boosts Zimmer Biomet's growth profile.
Positive
Zacks Investment Research
2 weeks ago
ZBH's Q4 Earnings Beat, Margins Contract, Stock Down in Premarket
Zimmer Biomet benefits from its diversified portfolio outside of core orthopedics and the company's strategic investments in attractive, higher-growth segments.
Negative
Benzinga
2 weeks ago
Why Is Zimmer Biomet Stock Trading Lower On Thursday?
On Thursday, Zimmer Biomet Holdings, Inc ZBH reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30.
Neutral
Seeking Alpha
2 weeks ago
Zimmer Biomet Holdings, Inc. (ZBH) Q4 2024 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q4 2024 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants David DeMartino - Senior Vice President-Investor Relations Ivan Tornos - President and Chief Executive Officer Suketu Upadhyay - CFO and EVP, Finance, Operations and Supply Chain Conference Call Participants Robbie Marcus - JPMorgan Patrick Wood - Morgan Stanley Steven Lichtman - Oppenheimer and Company Matt Taylor - Jefferies David Roman - Goldman Sachs Vik Chopra - Wells Fargo Ryan Zimmerman - BTIG Danielle Antalffy - UBS Travis Steed - Bank of America Rick Wise - Stifel Matt Miksic - Barclays Jayson Bedford - Raymond James Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, February 06, 2025.
Positive
Zacks Investment Research
2 weeks ago
Zimmer (ZBH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Negative
Reuters
2 weeks ago
Zimmer Biomet forecasts 2025 profit below estimates
Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar.
Positive
Zacks Investment Research
2 weeks ago
Zimmer Biomet (ZBH) Surpasses Q4 Earnings and Revenue Estimates
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $2.20 per share a year ago.
Positive
Zacks Investment Research
2 weeks ago
Unveiling Zimmer (ZBH) Q4 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zimmer (ZBH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Neutral
PRNewsWire
3 weeks ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Paragon 28, Inc.
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Paragon 28, Inc. (NYSE: FNA) and its board of directors concerning the proposed acquisition of the company by Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Stockholders will receive $13.00 and a contingent value right for up to $1.00 for each share of Paragon 28 stock that they hold.
Charts implemented using Lightweight Charts™